Literature DB >> 6170656

Treatment of scabies and pediculosis with lindane preparations: an evaluation.

B Shacter.   

Abstract

Risks and benefits involved in the use of lindane preparations for the treatment of scabies and head louse infestations are evaluated. Although lindane per si is moderately toxic, capable of inducing neurotoxic and hemotoxic effects, there is little evidence that the preparations used in the treatment of scabies and pediculosis give rise to toxic symptoms when applied according to directions. Current evidence does not support the view that lindane is intrinsically carcinogenic, although very high doses have induced hepatomas in mice. It is concluded that the benefits obtained in the use of lindane as a scabicide and pediculicide outweigh risks involved in its use for these purposes. Comparison with other preparations available for the control of scabies and pediculosis indicate that lindane is probably the most effective scabicide, although it also shows the greatest toxic potential. Malathion and pyrethrin preparations seem equally effective against head lice. Suggestions for even safer use of lindane are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6170656     DOI: 10.1016/s0190-9622(81)70111-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

Review 1.  Pharmacotherapy of ectoparasitic infections.

Authors:  T C Roos; M Alam; S Roos; H F Merk; D R Bickers
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Is the treatment of scabies hazardous?

Authors:  C Wilkinson
Journal:  J R Coll Gen Pract       Date:  1988-10

3.  Lindane binding to sections of human skin: skin capacity and isotherm determinations.

Authors:  E Menczel; D Bucks; H Maibach; R Wester
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

Review 4.  Treatment of Pediculosis Capitis.

Authors:  Prashant Verma; Chaitanya Namdeo
Journal:  Indian J Dermatol       Date:  2015 May-Jun       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.